Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
- Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
- Ginger products — Manage nausea with ginger chews or ginger tea.
- Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
- Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
The semaglutide landscape has shifted significantly in May 2026. Ozempic oral tablets are now at pharmacies, Wegovy HD is available, and the pipeline behind them keeps growing. Here's what you need to know.
1. Ozempic Oral Tablets Now at US Pharmacies (May 4)
Ozempic oral tablets launched at US pharmacies on May 4, 2026. This is a milestone: the first oral peptide GLP-1 receptor agonist with demonstrated MACE (Major Adverse Cardiovascular Events) reduction.
Available doses:
- 1.5 mg — Starting dose
- 4 mg — Maintenance dose
- 9 mg — Higher maintenance dose
Like Rybelsus, the tablets require taking on an empty stomach with no more than 4 oz of water, then waiting 30 minutes before eating or drinking. If you want an oral GLP-1 without food restrictions, Foundayo is an alternative — but it uses a different drug (orforglipron), not semaglutide.
For the full breakdown of oral GLP-1 options, see our GLP-1 Pill Guide and Wegovy Pill Doses.
2. Wegovy HD (7.2 mg) — Approved and Available
The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, after a 54-day fast-track review. It's triple the standard 2.4 mg maintenance dose.
Key data:
- 20.7% average weight loss at 72 weeks in clinical trials
- Not a starting dose — for patients already on 2.4 mg Wegovy for at least 4 weeks
- Now available at pharmacies as of April 2026
Wegovy HD is for people who plateaued on the standard dose and need more. See our full Wegovy HD Guide for eligibility, dosing, and side effects.
3. Wegovy Pill (Oral Semaglutide 25 mg) — Already Available
Separate from the Ozempic tablet above, the Wegovy pill (oral semaglutide 25 mg) is a distinct weight-management product that the FDA approved in December 2025 and Novo Nordisk launched at US pharmacies in January 2026. In the OASIS 4 trial, adherent patients lost an average of 16.6% of body weight. A 50 mg dose was studied in the earlier OASIS 1 trial (~15% weight loss) but remains investigational and is not FDA-approved.
This gives patients another needle-free option beyond the 9 mg ceiling of the diabetes-indicated Ozempic tablet. See our Wegovy Pill Doses guide for the full titration schedule.
4. CagriSema — FDA Under Review, Decision Expected Late 2026
CagriSema combines semaglutide with cagrilintide (an amylin analog) for dual appetite suppression. Phase 3 REDEFINE 1 trial results showed 20.4% average weight loss over 68 weeks — beating semaglutide alone (13.7%).
Important: CagriSema is not approved. Novo Nordisk submitted its FDA application in late 2025, and a decision is expected in late 2026 or early 2027. If approved, launch would likely follow in 2027.
Read the full breakdown in our CagriSema guide.
5. Generic Timeline: Still Years Away
Semaglutide does not yet have a generic version in the United States. Key dates:
| Brand | Earliest Expected Generic |
|---|---|
| Ozempic | 2031 |
| Wegovy | 2032 |
Patent litigation could shift these dates, but for now, no generic semaglutide is coming soon. The compounded semaglutide market continues to evolve, but compounded drugs are not FDA-approved and carry quality risks. For ongoing product liability cases, see our Ozempic lawsuits tracker.
See our Semaglutide Generic Availability guide for the full picture.
6. Novo Nordisk Shortage Status
Supply is improving as of May 2026. Key points:
- Wegovy 2.4 mg is now more widely available
- Ozempic 1 mg and 2 mg still face periodic shortages
- Novo Nordisk and Eli Lilly have expanded manufacturing capacity
- Most doses are expected to be consistently available by late 2026
For current availability and what to do if your medication is out of stock, see our GLP-1 Shortages guide.
7. Mounjaro MACE Decision — Competitive Implications
Eli Lilly's Mounjaro (tirzepatide) is awaiting an FDA decision on its cardiovascular outcomes data, expected mid-2026. If Mounjaro receives a MACE indication, it would compete directly with Ozempic's established cardiovascular benefit — intensifying the GLP-1 market rivalry.
This matters because cardiovascular risk reduction is a key differentiator for Ozempic, and a MACE indication for Mounjaro could shift prescribing patterns. For cost comparisons across all GLP-1s, see our GLP-1 Cost Comparison guide.
The Bottom Line
May 2026 is a turning point for semaglutide. Oral tablets are now at pharmacies. Wegovy HD offers a new option for patients who need more. CagriSema could arrive by 2027. But generics remain years away, and some doses still face supply gaps. Work with your doctor to find the right option for you, and stay informed through reliable sources.
This article is for information only. Always talk to your doctor for personalized medical advice. For FDA updates, visit fda.gov.
